DongKoo Bio & Pharma Co Ltd
KOSDAQ:006620
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| KR |
D
|
DongKoo Bio & Pharma Co Ltd
KOSDAQ:006620
|
153.9B KRW |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
987B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
592.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
298.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.8B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
248.3B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
309B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.4B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
124.1B USD |
Loading...
|
Market Distribution
| Min | -646.5% |
| 30th Percentile | 12.8% |
| Median | 19.7% |
| 70th Percentile | 32.2% |
| Max | 54 001.3% |
Other Profitability Ratios
DongKoo Bio & Pharma Co Ltd
Glance View
DongKoo Bio & Pharm Co. Ltd. operates as a holding company engaged in the manufacture and sale of pharmaceutical products and health supplements. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-02-13. is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The major products include antihistamines, topical steroids, therapeutic agents for prostatitis, treatments for benign prostatic hyperplasia, atherosclerotic agents, and antibiotics, among others. The firm is involved in contract manufacturing organization business. The company manufactures and sells therapeutic for osteoporosis, antiviral agents, erectile dysfunction treatments, hepatic disease agents; painkillers; gum treatments. In addition, the Company is engaged in the manufacturing and sale of medical devices and cosmetics. The firm distributes its products within the domestic market and to overseas markets, including America and Europe.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for DongKoo Bio & Pharma Co Ltd is 60.3%, which is below its 3-year median of 61%.
Over the last 3 years, DongKoo Bio & Pharma Co Ltd’s Gross Margin has decreased from 60.7% to 60.3%. During this period, it reached a low of 60.3% on Oct 30, 2025 and a high of 61.4% on Mar 31, 2024.
